Home / 2020 / June / 17

Daily Archives: June 17, 2020

doTERRA Becomes the First Global Aromatherapy and Essential Oils Company to Join Research Institute for Fragrance Materials

Partnership will pioneer advanced essential oil research

PLEASANT GROVE, Utah, June 17, 2020 (GLOBE NEWSWIRE) — doTERRA today announced that it has been accepted as a supporting member of the world-renowned Research Institute for Fragrance Materials (RIFM). As the leading global aromatherapy and essential oils company, doTERRA was granted membership based on a unanimous vote from the organization’s board of directors. RIFM also invited doTERRA scientists to contribute their essential oils’ knowledge and expertise as part of the organization’s natural complex substances working group.

RIFM’s purpose is to gather and analyze scientific data, engage in testing and evaluation, distribute information, cooperate with official agencies, and encourage uniform safety standards related to the use of fragrance ingredients.

“Our reputation for the relentless pursuit of purity fostered a relationship between RIFM and doTERRA’s sourcing team, which led to the decision to pursue membership in the organization,” said Dr. Russell J. Osguthorpe, doTERRA’s chief medical officer. “This partnership is part of an initiative to perform safety assessments on natural complex substances, such as essential oils. RIFM produces the most authoritative and comprehensive fragrance safety evaluations in the world. Together, we will improve the worldwide understanding of the science and safety behind essential oils, as well as their uses aromatically, topically and internally.”

As members, doTERRA will have access to RIFM’s comprehensive database on fragrance and flavor ingredients, which provides upwards of 70,000 references that include more than 135,000 human health and environmental studies on more than 6,000 materials.

An independent expert scientific panel reviews all of RIFM’s research, and its conclusions form the basis for the standards set by the International Fragrance Association (IFRA). Using the most current, globally-recognized guidelines, RIFM has to date completed panel-approved safety assessments for more than 85% of the current volume of use by the fragrance industry.

“We are an organization that firmly believes that we can do so much better with the safety and understanding of natural complex substances when we bring more resources to the table and expert voices to the discussion,” said RIFM’s President, James C. Romine, PhD. “doTERRA offers a unique and valuable perspective to RIFM, and we look forward to its scientists’ ongoing contributions to our working group.”

About doTERRA

dōTERRA® International is an integrative health and wellness company and the world leader in the Global Aromatherapy and Essential Oils market. dōTERRA sources, tests, manufactures and distributes CPTG Certified Pure Therapeutic Grade® essential oils and essential oil products to over eight million dōTERRA Wellness Advocates and customers. Through industry leading responsible sourcing practices, dōTERRA maintains the highest levels of quality, purity and sustainability in partnership with local growers around the world through Cō-Impact Sourcing®. The dōTERRA Healing Hands Foundation®, a registered 501(c)(3) non-profit organization, offers resources and tools to global sourcing communities and charitable organizations for self-reliance, healthcare, education, sanitation, and the fight against human trafficking. Through the life-enhancing benefits of essential oils, dōTERRA is changing the world one drop, one person, one community at a time. To learn more, visit www.doterra.com.

About RIFM

RIFM is the international scientific authority for the safe use of fragrance materials. RIFM generates, evaluates and distributes scientific data on the safety assessment of fragrance raw materials found in personal and household care products. Through extensive research, testing and constant monitoring of all scientific literature available, RIFM maintains its Database as the most comprehensive source worldwide of physical-chemical, toxicological and eco-toxicological data associated with known fragrance and flavor materials. RIFM’s scientific findings are evaluated by an independent Expert Panel—an international group of dermatologists, pathologists, toxicologists, reproduction, respiratory and environmental scientists. The Expert Panel evaluates the safety of fragrance ingredients under conditions of intended use and publishes its results in peer-reviewed scientific journals. The decisions of the Expert Panel regarding restrictions of use are published as IFRA Standards. For more information about RIFM, visit www.rifm.org.

Press Contact

Kevin Wilson

Informa Pharma Intelligence Names Ramsey Hashem As President

Former Chief Commercial Officer Assumes Role Today

LONDON, June 17, 2020 (GLOBE NEWSWIRE) — Informa Pharma Intelligence, the global business intelligence leader for the biopharma industry, today announced that, effective July 1, Ramsey Hashem, Informa Pharma Intelligence’s Chief Commercial Officer, has been named President. Hashem will assume the role from Linda Blackerby, who is moving into non-executive roles after 11 years of successful service leading business units at Informa.

As President and CEO, Hashem will be responsible for overseeing the entire Global Pharma Intelligence operations as well as launching new intelligence products to support the pharmaceutical industry’s needs for more data-driven decisions. Hashem brings over 25 years of experience at companies like Thomson Reuters, Clarivate Analytics, Wolters Kluwer Health and GE Healthcare, as well as managing and directing commercial success for analytic product launches. In his role as CCO of Informa Pharma Intelligence, he’s been responsible for the company’s revenue and sales goals and implementing customer engagement into the organization’s workflow.

The transition to Hashem builds on Informa Pharma Intelligence’s recent success – including the launch of a COVID-19 content hub, designed to provide key information related to the global outbreak, and a recent partnership with Signals Analytics, to provide data helping uncover trends and novel insights for life sciences companies mitigating investment risk and accelerating the drug development process.

“I’ve worked with Ramsey for the past 3 years, and I strongly feel he has the right experience, track record and skills to lead our business forward,” said Linda Blackerby, Informa Pharma Intelligence’s outgoing President. “His keen understanding of building and motivating teams to drive customer-centric results, and his experience collaborating across teams to drive real, tangible results will deliver continued success for Informa Pharma Intelligence. I have witnessed firsthand his ability to create a balanced work environment for his employees to perform at their best by fostering trust, collaboration and creativity.”

“I’ve been in the information business my entire career.  I have always valued Informa Pharma Intelligence’s commitment to providing innovative solutions to businesses in the biopharma industry. The work we’ve been able to accomplish has led to drastic change and progress in how pharmaceutical companies develop effective treatments,” said Ramsey Hashem, Informa Pharma Intelligence, President.  “Linda has been an outstanding leader as President and CEO of Pharma Intelligence, and I’m looking forward to continuing her legacy of building relationships with our industry partners and customers and gaining additional industry recognition.”

About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products—Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Biomedtracker, Scrip, Pink Sheet and In Vivo – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.

Media Contacts:
Diffusion PR for Informa Pharma Intelligence


Novavax Announces Additions to Executive Leadership

Dr. Filip Dubovsky appointed SVP, Chief Medical Officer Silvia Taylor appointed SVP, Investor Relations and Corporate Affairs

GAITHERSBURG, Md., June 17, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of two senior executives to the leadership team. Filip Dubovsky, M.D., MPH, FAAP, has been appointed Senior Vice President and Chief Medical Officer, where he will oversee Novavax’ medical and clinical affairs and related activities. Novavax also appointed Silvia Taylor, MBA, as Senior Vice President, Investor Relations and Corporate Affairs, overseeing Novavax’ investor relations, public relations and corporate communications activities.

“Novavax’ considerable progress and significant near-term milestones make the additions of Filip and Silvia to our leadership team both timely and important,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “With the addition of these two senior leaders, we are adding expertise to critical areas of the organization. We welcome them both.”

A recognized leader in vaccine development, Dr. Dubovsky brings more than 20 years of infectious disease experience to Novavax. He joins Novavax from AstraZeneca, where he was Head of Clinical Engagement and Policy and Deputy Chief Medical Officer for clinical affairs. He joined MedImmune, the global biologics arm of AstraZeneca, where he oversaw the clinical development of early and late-stage infectious disease and vaccine assets. Previously, he created and managed a portfolio of 25 malaria vaccine candidates spanning early candidate optimization to Phase 3 clinical studies at PATH’s Malaria Vaccine Initiative. He has co-authored more than 50 peer-reviewed scientific publications and currently sits on the Board of Directors of the Sabin Institute. Dr. Dubovsky earned his Master of Public Health degree from Johns Hopkins University and his Doctor of Medicine degree from the University of Alabama. He completed his pediatric training at Stanford University, his pediatric infectious disease fellowship at the Center for Vaccine Development at the University of Maryland, and his preventive medicine training at Johns Hopkins University.

“The recent scientific achievements by the Novavax team, including positive Phase 3 NanoFlu results and Phase 1/2 clinical trial initiation of NVX-CoV2373 to address the global coronavirus pandemic are impressive,” said Dr. Dubovsky. “I am eager to put my experience to work to help Novavax deliver these novel vaccines to healthcare practitioners and reduce the spread of these harmful diseases worldwide.”

Ms. Taylor brings more than 25 years of communications and commercial leadership to Novavax. Most recently, she was Vice President of Global Corporate Affairs and Communications at Autolus Therapeutics plc, where she led all financial, scientific and corporate communications. Prior to Autolus, Ms. Taylor was Senior Vice President of Global Investor Relations and Corporate Affairs at Sucampo. Earlier in her career, she held positions of increasing responsibility at MedImmune, the global biologics arm of AstraZeneca, including head of marketing responsible for the commercialization of the company’s respiratory syncytial virus and influenza franchises, as well as roles at Pfizer, where she served in key brand and consumer marketing roles. She has also worked in public relations and communications roles in agency and non-profit settings. Ms. Taylor earned a Master of Business Administration degree from Columbia University and a Bachelor of Arts in Foreign Affairs from University of Virginia.

“I am delighted to join Novavax during this incredibly productive period,” said Ms. Taylor. “It is an exciting opportunity to help tell the company’s compelling story as it brings innovative vaccines to patients, and to help deepen Novavax’ relationships with a broad array of important stakeholders.”

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products, including statements regarding the manufacturing of vaccine antigen dose amounts and timing, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (SEC) and updated by any Quarterly Report on Form 10-Q, particularly the risks inherent to developing novel vaccines. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Novavax, Inc.
Silvia Taylor and Erika Trahan

Brandzone/KOGS Communication
Edna Kaplan

Fitch Ratings affirmed CNH Industrial N.V.’s and CNH Industrial Capital LLC’s Long-Term Issuer Default Ratings at ‘BBB-‘ and changed Outlook to Stable

London, June 16, 2020

CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces that on June 15, 2020, Fitch Ratings (“Fitch”) affirmed CNH Industrial N.V.’s and CNH Industrial Capital LLC’s Long-Term Issuer Default Ratings at ‘BBB-‘ and changed the Outlook from Positive to Stable.

CNH Industrial N.V. (NYSE: CNHI /MI: CNHI) is a global leader in the capital goods sector with established industrial experience, a wide range of products and a worldwide presence. Each of the individual brands belonging to the Company is a major international force in its specific industrial sector: Case IH, New Holland Agriculture and Steyr for tractors and agricultural machinery; Case and New Holland Construction for earth moving equipment; Iveco for commercial vehicles; Iveco Bus and Heuliez Bus for buses and coaches; Iveco Astra for quarry and construction vehicles; Magirus for firefighting vehicles; Iveco Defence Vehicles for defence and civil protection; and FPT Industrial for engines and transmissions. More information can be found on the corporate website: www.cnhindustrial.com


Corporate Communications

Email: mediarelations@cnhind.com

Investor Relations

Email: investor.relations@cnhind.com


REMINDER – Bombardier Announces Virtual Annual Meeting of Shareholders

MONTREAL, June 16, 2020 (GLOBE NEWSWIRE) — Bombardier (TSX: BBD.B) will host its 2020 Annual Meeting of Shareholders (“Meeting”) on June 18, 2020 at 10:30 EDT in a virtual format due to the ongoing public health concerns related to the COVID-19 pandemic.

The Corporation previously announced in its 2020 Notice of Meeting that, subject to public health conditions and concerns, it would host a hybrid Meeting format, whereby registered shareholders and duly appointed proxyholders could attend and participate either in person or via a live webcast. However, given the continued risks associated with hosting gatherings during the COVID-19 pandemic, the Company has made the decisions to adopt a pure virtual format with no in-person participation.

Bombardier therefore welcomes all registered shareholders and duly appointed proxyholders who wish to participate to the online Meeting to do so by joining the live webcast available at https://web.lumiagm.com/122776078. As usual, only registered shareholders and duly appointed proxyholders will be allowed to vote and intervene during the live Meeting. Unregistered shareholders, guests and media will be able to watch the online Meeting via the live webcast available at the same link.

Instructions to vote and participate in the online Meeting, including submitting questions to management and to the Chairman of the Board of Directors of Bombardier, will be available on the Corporation’s website here and on the online Meeting platform. Bombardier encourages shareholders to vote and submit their proxies prior to the Meeting.

About Bombardier
With nearly 60,000 employees across two business segments, Bombardier is a global leader in the transportation industry, creating innovative and game-changing planes and trains. Our products and services provide world-class transportation experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montreal, Canada, Bombardier has production and engineering sites in over 25 countries across the segments of Aviation and Transportation. Bombardier shares are traded on the Toronto Stock Exchange (BBD). In the fiscal year ended Dec. 31, 2019, Bombardier posted revenues of $15.8 billion. News and information at bombardier.com or follow us on Twitter @Bombardier.

Bombardier is a registered or unregistered trademarks of Bombardier Inc. or its subsidiaries.

For Information
Jessica McDonald
Advisor, Media Relations and Public Affairs
Bombardier Inc.
+1 514 861 9481

European Markets on Upswing Wednesday

European markets are trading higher Wednesday with investors riding on new hopes of a swift post-pandemic recovery.

The FTSE index in London has gained 0.5% in midday trading, the CAC-40 in Paris is up 0.7%, and Frankfurt’s DAX index is 0.4% higher.

Asian markets ended their Wednesday trading sessions mostly higher, with Sydney’s S&P/ASX index gaining 0.8% to lead the region.  Hong Kong’s Hang Seng index ended 0.5% higher, Shanghai’s Composite and Seoul’s KOSPI indices both gained 0.1%, and Taiwan’s TSEC is 0.2% higher.


Tokyo’s Nikkei index finished its trading session 0.5% lower, while Mumbai’s Sensex was down 0.2%.

Oil markets are in a slump Wednesday, with U.S. crude selling at $38.09 per barrel, down 0.7%, while Brent crude, the international benchmark, selling at $40.79, down 0.4%.

All three U.S. indexes continue to trend in a positive direction Wednesday indicating a good opening for Wall Street a day after making solid gains thanks to new data showing U.S. retail sales rose a record 17.7% in May, the biggest one-month increase in history.



In Italy, ‘A Fantastic Feeling’ as Signs of Normalcy Return

ROME – As a downward trend for both coronavirus fatalities and new confirmed cases continues, Italy has entered Phase Three with the reopening of nearly all businesses and activities. With the country having suffered more than 34,000 deaths from COVID-19 and no vaccine yet available, cautionary measures and rules on how to behave mainly in closed spaces are expected to be around for some time.

Italy, an early epicenter of the coronavirus outbreak in Europe, has been gradually re-opening over the past few weeks. When it started to come out of its tight lockdown, Prime Minister Giuseppe Conte said that the months ahead would largely depend on the behavior of Italians and did not rule out future lockdowns if new clusters emerged.


Italians are aware the virus has not been completely defeated yet and many appear to understand they still need to follow certain rules.

Posters and signs remind customers at stores and public spaces about the need to maintain social distancing, wear protective masks and sanitize one’s hands. In some places, such as airports, there are temperature checks and people with more than 37.5 Celsius must return to their homes.

After a lockdown that seemed to never end, many Italians appear happy to comply with the regulations.

To the joy of many, the latest businesses to reopen this week were cinemas and theaters. No more than 200 people can enter closed venues and at outdoor events there can be a maximum of 1,000.

For many, the reopening of movie theaters was an emotional moment.

A young Rome resident, who went back to the cinema as soon as it re-opened its doors, said that it was a “fantastic feeling” because after months at home watching TV, being able to watch a movie on the big screen eating warm popcorn is priceless.

Young people especially are ready for summer fun, as nightclubs and discos also re-opened, but club owners are expressing concerns that it will be very difficult to enforce some of the rules that include customers having to dance one meter apart.


Large-scale gatherings of all kinds are still banned, but amateur contact sports will resume from June 25th and schools are expected to reopen in September.

Coronavirus border restrictions have been easing throughout Europe. By Wednesday, only travelers from outside the European Union were still being required to quarantine upon arriving in Italy.